

antibiotics is acquired mainly by target alterations but in a few cases, the antibiotic chemical moieties are modified; that the primary action of most antibiotics that induce significant local or allosteric conformational alterations is to inhibit functional activities rather than to merely block vital locations; and that most proteins that interact with antibiotics are involved in dynamic aspects of ribosomal function.

Although a precise understanding of all processes associated with antibiotic action is still incomplete, the current findings justify modest optimism and it appears that the elucidation of the common principles, combined with the genetic, structural, and biochemical investigations should lead to structure-based approaches for devising modifications of existing antibiotics as well as in the design of novel potent anti-infective drugs.

Keywords: ribosomes, antibiotics, resistance

MS94.30.2

Acta Cryst. (2005). A61, C119

Inhibitors of the Eukaryotic 20S Proteasome Core Particle: a Structural Approach

Michael Groll, Adolf Butenandt-Institut, Lehrstuhl Physiologische Chemie, Butenandtstr. 5, 81377 München. E-mail: michael.groll@bio.med.uni-muenchen.de

The ubiquitin-proteasome pathway is particularly important for the regulated degradation of various proteins which control a vast array of biological processes. Therefore, proteasome inhibitors are promising candidates for anti-tumoral or anti-inflammatory drugs. N-Acetyl-Leu-Leu-Norleucinal was one of the first proteasome inhibitors discovered and has been widely used to study the 20S proteasome core particle (CP) function *in vivo*, despite its lack of specificity. Vinyl sulfones, like Ac-PRLN-vs, show covalent binding of the β -carbon atom of the vinyl sulfone group to the Thr10⁷ only of subunit β 2. However, vinyl sulfones have similar limitations as peptide aldehydes as they have been reported also to bind and block intracellular cysteine proteases. A more specific proteasome inhibitor is the natural product lactacystin, which can be isolated from *Streptomyces*. It was found that this compound forms an ester bond only to the Thr10⁷ of the chymotrypsin like active subunit β 5 due to specific P1 interactions. In contrast to most other proteasome inhibitors, the natural α , β '-epoxyketone peptide epoxomicin binds specifically to the small class of N-terminal nucleophilic (Ntn) hydrolases with the formation of a morpholino adduct.

All previously described proteasome inhibitors bind covalently to the proteolytic active sites. However, as the proteasome is involved in a variety of biological important functions, it is of particular interest to block the CP only for limited time in order to reduce cytotoxic effects. Recently, the binding mode of the natural specific proteasome inhibitor TMC-95 obtained from *Apiospora montagnei* was investigated. The crystal structure revealed that the TMC-95 blocks the active sites of the CP non-covalently in the low nM range.

Keywords: proteasome, ubiquitin, drug design

MS94.30.3

Acta Cryst. (2005). A61, C119

Computational Modeling of GPCRS: Insight into the Function of the most Privileged Drug Targets

Francesca Fanelli^{a,b}, Pier. G. De Benedetti^b, ^aDulbecco Telethon Institute. ^bDepartment of Chemistry, University of Modena and Reggio Emilia. E-mail: fanelli@unimo.it

G protein coupled receptors (GPCRs) constitute the largest and most important superfamily of signal transduction membrane proteins known to date. Our study is aimed at understanding, through computational modeling, the molecular mechanisms of GPCR functioning either in their normal conditions or when hit by gain-of-function or loss-of-function mutations. Molecular simulations of the wild type form of luteinizing hormone receptor (LHR) as well as of its spontaneous and engineered mutants were instrumental to infer the structural features, which differentiate the mutation-induced active from the inactive states of this receptor [1]. These features were translated into computational indices instrumental in *in silico*

functional screening of novel LHR mutants [1]. Similarly to mutation-induced activation, the interface between the cytosolic extensions of helices 3 and 6 is the target of the structural modifications induced by activating ligands (i.e. agonists). The chemical information transfer from the agonist binding site (on the extracellular side) to the cytosolic domains is mediated by a cluster of aromatic amino acids in helix 6 [1] Computational modeling of the supramolecular organization of GPCRs and their intracellular partners is the current challenge towards a deep understanding of their mechanism of functioning.

[1] Fanelli F., De Benedetti P.G., *Chem. Rev.*, *in press*.

Keywords: GPCR, computational modeling, virtual screening

MS94.30.4

Acta Cryst. (2005). A61, C119

Structure-Based Design of New AIDS Drugs: Overcoming Drug Resistance

Kalyan Das^a, Arthur D. Clark Jr.^a, Paul J. Lewi^b, Stephen H. Hughes^c, Paul A. J. Janssen^b, Eddy Arnold^a, ^aCABM & Rutgers University, New Jersey, USA. ^bJanssen Pharmaceutica NV, Vosselaar, Belgium. ^cNIH National Cancer Institute-Frederick, Maryland, USA. E-mail: kalyan@cabm.rutgers.edu

Drug resistance is a primary cause of AIDS treatment failure. A multidisciplinary effort [1] led to the discovery of the potent diaryl-pyrimidine (DAPY) nonnucleoside inhibitors (NNRTIs) dapivirine, etravirine, and rilpivirine that are under clinical evaluation. Systematic structural and modeling studies of HIV-1 reverse transcriptase (RT) in complexes with NNRTIs used in the drug design effort revealed different modes of binding for the DAPY inhibitors [2]. The torsional flexibility ("wiggling") of the inhibitors can generate numerous conformational variants and the compactness of the inhibitors permits repositioning and reorientation (translation and rotation) within the pocket ("jiggling"). Such adaptations appear to be critical for the ability of the NNRTIs to retain their potency against a wide range of drug-resistant HIV-1 RTs. Exploitation of inhibitor conformational flexibility can be a powerful element of drug design, especially for the design of drugs that will be effective against rapidly mutating targets.

[1] Janssen P.A.J., et al., *J. Med. Chem.*, 2005, *in press*. [2] Das et al., *J. Med. Chem.*, 2004, **47**, 2550.

Keywords: drug design, drug resistance, reverse transcriptase

MS94.30.5

Acta Cryst. (2005). A61, C119-C120

Evaluation of Docking Results by Diffraction-component Precision Index (DPI)

Noriaki Hirayama^a, Junichi Goto^b, Ryoichi Kataoka^b, ^aTokai University School of Medicine, Isehara, Japan. ^bRyoka Systems Inc., Urayasu, Japan. E-mail: hirayama@is.icc.u-tokai.ac.jp

Since efficient docking technique can be a powerful tool for the computer-aided drug design, many different approaches to solving the docking problems have been proposed. The reliability of the docking results has not been quantitatively discussed. Relatively subjective criteria have been generally applied to evaluate the docking results so far. The DPI introduced by Cruickshank[1] is 'a good and rough guide' to coordinate precision and can be used to evaluate the reliability of the docking results.

In the docking study the most useful quantity to consider the docking results is an rmsd between predicted and experimental heavy-atom coordinates of the ligand structure. Suppose the standard uncertainty of the observed and predicted molecular model is the same in magnitude and equals to σ , the estimated standard uncertainty of the rmsd between the corresponding atoms in the observed and predicted molecule can be approximated to be $\sqrt{2} \sigma$. Therefore the magnitude of the rmsd value can be evaluated using the estimated uncertainty.

We have recently developed a unique docking algorithm named Ph4Dock[2] and the docking results obtained by Ph4Dock were evaluated using DPI. The present study has demonstrated that DPI is a good measure to judge the quality of docking results.